Visual impairment significantly alters the quality of life of people with Multiple Sclerosis (MS). The objective of this study was to identify predictors (independent variables) of visual outcomes, and to define their relationship with neurological disability and retinal atrophy when assessed by optical coherence tomography (OCT). We performed a cross-sectional analysis of 119 consecutive patients with MS, assessing vision using high contrast visual acuity (LogMar), 2.5% and 1.25% low contrast visual acuity (Sloan charts), and color vision (Hardy-Rand-Rittler plates). Quality of vision is a patient reported outcome based on an individual's unique perception of his or her vision and was assessed with the Visual Functioning Questionnaire-25 (VFQ-25) with the 10 neuro-ophthalmologic items. MS disability was assessed using the expanded disability status scale (EDSS), the MS functional composite (MSFC) and the brief repetitive battery-neuropsychology (BRB-N). Retinal atrophy was assessed using spectral domain OCT, measuring the thickness of the peripapillar retinal nerve fiber layer (pRNFL) and the volume of the ganglion cell plus inner plexiform layer (GCIPL). The vision of patients with MS was impaired, particularly in eyes with prior optic neuritis. Retinal atrophy (pRNFL and GCIPL) was closely associated with impaired low contrast vision and color vision, whereas the volume of the GCIPL showed a trend (p = 0.092) to be associated with quality of vision. Multiple regression analysis revealed that EDSS was an explanatory variable for high contrast vision after stepwise analysis, GCIPL volume for low contrast vision, and GCIPL volume and EDSS for color vision. The explanatory variables for quality of vision were high contrast vision and color vision. In summary, quality of vision in MS depends on the impairment of high contrast visual acuity and color vision due to the disease.
Citation: Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, et al. (2018) Predictors of vision impairment in Multiple Sclerosis. PLoS ONE 13(4): e0195856. https://doi.org/10.1371/journal.pone.0195856
Editor: Sanjoy Bhattacharya, Bascom Palmer Eye Institute, UNITED STATES
Received: December 3, 2017; Accepted: March 31, 2018; Published: April 17, 2018
Copyright: © 2018 Sanchez-Dalmau et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: Raw data of the study is submitted as a supplementary file.
Funding: This work was supported by the Instituto de Salud Carlos III with FEDER funds (”Otra forma de hacer Europa”) from the European Commission (PI15/0061, to PV; PI15/00587 to SL and AS), the Spanish MS Network (REEM: RD16/0015/0002 to AS; and RD16/0015/0003 to PV), and CERCA Programme / Generalitat de Catalunya. VA is an employee of Trial Form Support (TFS) and she was in charge of the statistical analysis. TFS provided support in the form of salaries for authors [VA], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. The corresponding author has full access to data and analysis.
Competing interests: BSD, IZ, IPV, MS, YB, NSV, SA, AG, MA and LSV have nothing to declare. EHML received consultancy fees from Genzyme, and unrestricted grants from Merck, Marato TV3 Foundation and the International Cellex Foundation. SL received remuneration from Merck-Serono, Biogen-Idec, Teva Pharmaceutical Industries Ltd and Novartis for providing consulting services and offering lectures. AS received remuneration from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis for providing consulting services and offering lectures. VA is an employee of TFS, Barcelona, Spain. This does not alter our adherence to PLOS ONE policies on sharing data and materials. PV holds stocks in Bionure, Spiral Bioventures, MintLabs and Health Engineering and is currently an employee of Genentech. This does not alter our adherence to PLOS ONE policies on sharing data and materials.AS received remuneration from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd and Novartis for providing consulting services and offering lectures.
Visual impairment is a common feature in people with multiple sclerosis (MS)[1, 2]. High contrast visual acuity (HCVA) assessment is considered not to be sufficiently sensitive to capture visual impairment in MS patients, and low contrast visual acuity (LCVA) and color vision are more sensitive parameters of vision for MS patients[2, 6, 7]. Quality of vision is a patient reported outcome based on an individual's unique perception of his or her vision. The quality of vision in MS patients can be evaluated using the validated Visual Functioning Questionnaire-25 (VFQ25) with the addition of 10 neuro-ophthalmological items, which would help to improve the characterization of the disease impact in people with MS.
Considering the negative impact of visual impairment on MS patients, understanding how specific visual abnormalities or retinal atrophy impair the quality of vision will be particularly relevant to improve the care of people with MS. Moreover, defining these relationships could identify the most informative visual tests to include in multi-domain disability scores to monitor MS. Therefore, the objective of this study was to investigate the contribution of retina atrophy and disability to vision, and to identify the main predictors (significant independent variables in the multivariate regression) of visual outcomes.
The Barcelona MS-VisualPath cohort is an ongoing prospective study of patients with MS conducted at the Hospital Clinic of the University of Barcelona, Spain. The design and methods employed by the MS-VisualPath cohort have been described in detail elsewhere. Briefly, the cohort included MS patients diagnosed according to McDonald Criteria without any psychiatric, neurological or ocular disorders that may interfere the aims of the study. We excluded measurements from eyes with severe refractive errors (myopia > −6.0 dp or an axial eye length >26 mm; hypermetropia > 5 dp; cylinder > 3 dp), optic nerve drusen, cataracts, current or prior glaucoma, acute optic neuritis (ON) (<6 months), or other causes of visual loss not attributable to MS. The first consecutive 119 patients of this prospective cohort were included in this cross-sectional analysis. Patients were given a complete examination that included neurological evaluation, visual function testing and optical coherence tomography.
The Institutional Review Board at the Hospital Clinic of Barcelona approved the study and all participants provided their written informed consent prior to enrollment.
We collected demographic (gender and age) and MS-related data (disease sub-type, disease duration since first symptom onset, history of prior ON, type of disease modifying treatment -DMT- and clinical disability) from the subjects, and they all underwent visual testing and OCT evaluation during remission (patients were > 30 days from relapse). The presence of prior ON was assessed in the electronic medical records, as indicated previously, considering classical clinical presentation semiology and standard examinations described previously. Eyes classified as non-ON eyes have neither prior nor acute ON.
We assessed global neurological disability using the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC). Cognitive performance was evaluated with the Brief Repeatable Battery-Neuropsychology test (BRB-N), including separate scores for verbal memory, visual memory, executive function (e.g. Symbol Digit Modality Test -SDMT) and verbal fluency.
A trained optometrist carried out the ophthalmological evaluations separately on each eye (visual acuity and color vision). Before assessing visual acuity and color vision, refraction was evaluated in all patients, even in those wearing their own glasses or contact lens. Optical refraction was corrected with the prescription lenses necessary in each case, positive lenses for hyperopia, negative lenses for myopia or cylinder lenses for astigmatism. The trial lenses frame was used to correct refraction at the same time. The optometrist (SA) evaluated monocular and binocular high visual acuity, low visual acuity and color vision. We evaluated HCVA using ETDRS charts and transformed the scores into logMar units for statistical analysis. LCVA was scored with the 2.5% and 1.25% low-contrast Sloan charts and it are based on the number of letters correctly identified (up to 70). Color vision acuity was assessed using Hardy-Rand-Rittler (HRR) plates, and based on the number of symbols identified correctly (up to 36).
The impact of vision was evaluated with a self-reported quality of vision assessment using VFQ25 (global and with the 10 neuro-ophthalmological supplement), as described previously. The cut-off of abnormal visual quality was defined as: Global score < 88; 10-neuro-ophthalmological items < 79; and Combined score < 85.
Retinal image acquisition and analysis
Retinal scans were performed at a single center by a trained technician (SA) using a Spectralis® SD-OCT device (Heyex 5.30 Heidelberg Engineering, Heidelberg, Germany) in eye-tracking mode, under standard ambient lighting (80–100 foot-candelas) and without pupillary dilation. Spherical errors were adjusted prior to each measurement and the pRNFL thickness (μm) was measured using a 12-degree diameter ring scan automatically centered on the optic nerve head (100 ART; 1,536 A Scans per B scan). The macular scan protocol involved a 20x20 degree raster scan (horizontal orientation) centered on the fovea, taking 25 horizontal sections separated by 240 μm and with a mean ART≥9 [512 A Scans per B scan].
Retinal layer segmentation was performed automatically using the in-built HRA/Spectralis Viewer Module (v.220.127.116.11) for peripapillary scans and the Viewer Module (6.0c version) for macular raster-scans to quantify the macular GCIPL volume. A single optometrist (SAA) reviewed all the images from the automated segmentation and performed manual correction for obvious errors. All images were carefully reviewed to ensure they fulfilled OSCAR-IB and APOSTEL criteria [21, 22]. Conversion of volumes (original measurement in mm3) to thicknesses (in μM) of the different layers was conducted using the following equation:
Categorical variables were compared using a Chi-squared or Fisher´s exact test. Continuous variables were compared with an independent two-sample t-test after confirming their normal distribution (Shapiro-Wilks test) or with a Mann-Whitney-Wilcoxon U test when a normal distribution could not be assumed. Linear regression analyses with dummy variables (binary variables (0 or 1) for categorical variables such as sex or previous ON) were used to assess the association between the clinical outcome measures and retinal atrophy assessed on an individual patient level in a model that included age, sex, history of MS-ON, EDSS and the use of DMTs. Additionally, linear regression analyses with dummy variables were used to identify predictors (independent variables) of visual outcomes. We selected the significant variables in the univariate linear regression and they were included in the multivariate model for each visual variable. A stepwise selection method was applied to select the significant variables in the final model. Analyses were performed on a patient level in order to relate the global outcomes (quality of vision (VFQ-25 and VFQ25+10items [8, 9, 20]), disability scales) with visual acuity or retinal thickness. For the multiple regression analysis we make use of the vision variables that should be more informative for global scales (quality of vision or neurological disability (EDSS)) and for this reason we made use of the binocular visual acuity (HCVA, LCVA and HRR). We used the mean of both eyes instead of adjusting for inter-eye correlation because such approach provides very similar results as previously described. All p-values were two-tailed and they were considered significant at p ≤0.05. Statistical analyses (VA) were performed using the SAS Enterprise Guide 7.1 software. Raw data of the study is available in S1 and S2 Files.
Characteristics of the MS cohort
The cohort was composed of 119 patients with MS, two thirds of whom were female. The mean disease duration of the cohort was 12 years (SD 7.5) and the patients were predominantly of the RRMS subtype (105, 88.2%), while there were 10 SPMS (8.4%) and 4 PPMS (3.4%) patients. There were 65 patients with no prior ON, whereas 54 had suffered a previous episode of ON in at least one of their eyes. Most of patients were receiving a DMT, with 57 patients treated with interferon beta (47.8%), 15 with glatiramer acetate (12.6%), 2 with natalizumab (1.7%) and 13 with fingolimod (10.9%). There were 30 untreated patients (25.3%), which included patients with each progressive subtype. The patients were mildly disabled, with a median EDSS of 2.0 (range 1–7.5), a mean MSFC of 0.31 (SD 1.1) and a mean z score with the BRB-N of 0.19 (SD 0.8). When comparing the demographic and clinical characteristics of the cohort as a function of prior ON or not, the only significant difference beyond visual acuity, was that patients who had suffered a previous ON performed worse in the neuropsychological tests than patients without prior ON (Table 1).
As expected, MS patients with prior ON had significantly lower scores for LCVA and color vision than patients without a prior episode, whereas the differences between the subgroups for HCVA and quality of vision were not significant (Tables 1 and S1). The MS patients had a thinner retina, and the thickness of the pRNFL and the volume or thickness of the GCIPL were significantly lower in patients that had previously suffered ON than in patients that had not (Fig 1). Both measures of retina atrophy, pRNFL thickness and GCIPL volume, were significantly correlated with LCVA and color vision in the linear regression analyses adjusted for age, gender, history of ON, use of DMT and EDSS. The GCIPL volume showed a trend (p = 0.09) to be correlated with the combined score of the quality of vision (VFQ-25 +10 items) (Table 2 and Fig 2).
The graphs shows the mean pRNFL thickness (A) or GCIPL volume (B) for the overall cohort, and for patients with prior optic neuritis (ON) or with no prior optic neuritis (NON).
The scatter-plots show the correlation between visual acuity measured with HCVA, LCVA (either 2.5% or 1.25% contrast) or color vision (HRR) with the EDSS. Moreover, the scatter-plot of the correlation of the visual acuity associated with the thickness of the GCIPL (the 2.5%LCVA and the HRR) is shown on the bottom panels.
Cross-sectional predictive variables of visual outcomes
In order to identify which independent variables (predictors) might explain the visual outcomes, multiple regression analysis was performed to evaluate HCVA, LCVA, color vision and quality of vision. The independent variables included in all the models were sex, age, disease duration, previous ON, EDSS, MSFC, BRB-N z score, SDMT score, use of DMT, pRNFL thickness and GCIPL volume. The models analyzing the quality of vision also included HCVA, LCVA and color vision. The univariate analysis showed an association of HCVA with the EDSS, LCVA, HRR and the thickness of the pRNFL (S2 Table). The univariate analysis of the 2.5% LCVA found associations with EDSS, MSFC, DMT use, HCVA, HRR, thickness of the pRNFL and volume of the GCIPL (S3 Table). Regarding color vision, the variables associated in the univariate analysis were age, disease duration, previous ON, EDSS, HCVA, LCVA, pRNFL thickness and GCIPL volume (S4 Table). Finally, the variables associated with quality of vision were age, disease duration, EDSS, HCVA, LCVA, color vision and GCIPL volume (S5 Table).
The multivariate analysis for the HCVA showed that the only significant variable explaining HCVA was the EDSS (Table 3). In the case of LCVA (2.5% Sloan charts), the only significant variable in the stepwise approach was the GCIPL volume. Regarding color vision, the stepwise approach identified the GCIPL volume and the EDSS as explanatory variables. Finally, in terms of quality of vision, either VFQ-25 or the combined score with the 10 neuro-ophthalmological items, the explanatory variables were HCVA and color vision (Table 3).
The variables included are described in Table 1. The variables were selected using the stepwise method. To analyze visual acuity, the retinal layer thickness was multiplied by 10 to readily visualize the values.
The best model based on the R2 value obtained for visual acuity was that for color vision, which explained up to 45% of the HRR variability. Accordingly, a decrease of 1 unit in the GCIPL volume predicted a reduction of almost 1 point in the HRR and, a 1-point increase of the EDSS almost a 1-point decrease in the HRR. Regarding quality of vision, the models were similar for the VFQ-25 with and without the 10 neuro-ophthalmological items, and they explained almost 35% of the VFQ scores. As such, a 0.1 point increase in the HCVA predicted an almost 2.6 point decrease in the VFQ-25, whereas a 1 point decrease in the HRR predicted almost a 1 point decrease in the VFQ-25. Therefore, in our models, HCVA and color vision were the two variables that had significant effects on the quality of vision.
In this study we found impaired quality of vision was mainly dependent on HCVA and color vision. Color vision and LCVA are more sensitive test for detecting visual abnormalities for acute ON[6, 20], and as such, it was proposed to include such tests in MS patient assessments [2, 5, 7, 23]. However, our study identified that the main contributor to quality of vision was HVCA and color vision, probably due to the relevance of both types of visual function in the patient’s visual perception.
The multivariate analysis carried out here provides several insights into visual outcomes. HCVA was only dependent on global disability (EDSS) but not to retina atrophy, suggesting that this scale may be less sensitive to capture the damage observed in visual pathway in MS[2, 6]. In terms of LCVA and color vision, GCIPL volume was the main explanatory variable, confirming that the ganglion cell layer is the most sensitive retinal structure to explain the changes in visual function[24, 25]. As such, the GCIPL volume is proposed as a surrogate end-point to assess long-term visual disability[20, 25]. Indeed, the two best models to predict visual disability were those of color vision and quality of vision, although they explained not more than one third to a half of the variability. Accordingly, it is still necessary to develop accurate and sensitive measures of vision and predictive models that can be used to monitor patient disease course, and that can be used as accepted surrogate end-points in clinical trials.
Regarding quality of vision, we found that the main explanatory variables were HCVA and color vision but not LCVA or retinal atrophy. HCVA is critical for reading and other high definition vision functions; while changes in color vision are readily detected by patients and they alter their visual perception[2, 10]. Therefore, it may not be appropriate to use only retinal atrophy or LCVA as surrogates of quality of vision. Quality of vision is a complex outcome that involves not only visual acuity or color vision but also, motion perception, visual fields and other aspects related to the integration of overall visual activity in the patient’s daily activities. Like many other quality of life scales, individual assessment of visual sub-function is unlikely to explain its variability. In MS patients that have previously suffered ON and with a RNFL below 75μm, the VFQ-25 scores dropped approximately 2 points for every 1 μm decrease in the RNFL. Moreover, quality of vision has been related to poor vision[27, 28], low contrast vision[7, 23] or contrast sensitivity. Recently, quality of vision in MS patients was shown to be directly related with the thickness of the pRNFL (although it was not significant in Balk et al study (p = 0.06)) and the volume of GCIPL, both at the binocular and monocular level and irrespective of prior ON [25, 30]. However, in our study the multivariate analysis failed to confirm such associations, probably due to the low dispersion of the data in a mildly impaired population of MS patients compared with such studies, the use of a smaller sample size than Balk et al study or lack of power for stepwise analysis. Our finding that quality of vision was dependent on HCVA and color vision supports a close relationship between patient’s reported outcomes and neurological performance in the visual pathway.
There are several limitations to our study. First, we have performed a cross-sectional analysis, while longitudinal studies will be required to identify predictors of visual scores. Hence, we plan to perform a longitudinal assessment of the Barcelona MS-VisualPath cohort to validate our results. The cohort was of intermediate size and with a predominance of the RRMS sub-type, which limited our capacity to perform a stratified analysis based on disease duration or MS sub-type. Finally, a significant proportion of our cohort received DMTs and thus, our results are representative of current MS populations but they do not explain the natural history of the disease in terms of visual impairment.
In summary, our study shows that visual impairment is common in patients with MS and while it was more severe in patients that had previous suffered ON, it was also significant in patients that had not. The GCIPL volume was the most sensitive surrogate end-point, a parameter that can be used to monitor the disease course or as an end-point in clinical trials. Finally, we describe that HCVA and color vision are predictors of quality of vision.
S1 Table. 1.25% low contrast visual acuity assessment.
S2 Table. Univariate association with high contrast visual acuity.
S3 Table. Univariate association with low contrast visual acuity.
S4 Table. Univariate association with color vision.
S5 Table. Univariate association with vision-related quality of life.
- 1. Heesen C, Bohm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14(7):988–91. pmid:18505775.
- 2. Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain. 2015;138(Pt 1):11–27. pmid:25433914; PubMed Central PMCID: PMCPMC4285195.
- 3. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997;42(3):379–82. pmid:9307263
- 4. Balcer LJ, Baier ML, Pelak VS, Fox RJ, Shuwairi S, Galetta SL, et al. New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis. Mult Scler. 2000;6(3):163–71. Epub 2000/06/29. pmid:10871827.
- 5. Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Perez S, Llufriu S, Sepulveda M, et al. Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. J Neurol. 2015;262(11):2491–7. pmid:26259563.
- 6. Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, et al. Acute optic neuritis: Unmet clinical needs and model for new therapies. Neurology(R) neuroimmunology & neuroinflammation. 2015;2(4):e135. pmid:26236761; PubMed Central PMCID: PMC4516397.
- 7. Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):734–47. pmid:28206829; PubMed Central PMCID: PMCPMC5407511.
- 8. Ma SL, Shea JA, Galetta SL, Jacobs DA, Markowitz CE, Maguire MG, et al. Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol. 2002;133(5):686–92. pmid:11992867.
- 9. Raphael BA, Galetta KM, Jacobs DA, Markowitz CE, Liu GT, Nano-Schiavi ML, et al. Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol. 2006;142(6):1026–35. pmid:17046704.
- 10. Costello F. Vision Disturbances in Multiple Sclerosis. Semin Neurol. 2016;36(2):185–95. pmid:27116725.
- 11. Martinez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martinez-Heras E, Torres-Torres R, Ortiz-Perez S, et al. The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. BMC research notes. 2014;7:910. pmid:25512202; PubMed Central PMCID: PMC4300678.
- 12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. Epub 2011/03/10. pmid:21387374; PubMed Central PMCID: PMC3084507.
- 13. Gabilondo I, Martinez-Lapiscina EH, Martinez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol. 2014;75(1):98–107. Epub 2013/10/12. pmid:24114885.
- 14. Martinez-Lapiscina E, Arnow S, Wilson J, Saidha S, Preiningerova J, Oberwahrenbrock T, et al. Retinal thickness measured by optical coherence tomography and risk of disability worsening in multiple sclerosis. Lancet Neurol. 2016;15(6):574–84. pmid:27011339
- 15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52. pmid:6685237
- 16. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler. 1999;5(4):244–50. pmid:10467383
- 17. Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F, Garcea O, et al. Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test. Mult Scler. 2006;12(2):187–95. pmid:16629422
- 18. Cole BL, Lian KY, Lakkis C. The new Richmond HRR pseudoisochromatic test for colour vision is better than the Ishihara test. Clin Exp Optom. 2006;89(2):73–80. Epub 2006/02/24. doi: CXO015 [pii] pmid:16494609.
- 19. Martinez-Lapiscina EH, Ortiz-Perez S, Fraga-Pumar E, Martinez-Heras E, Gabilondo I, Llufriu S, et al. Colour vision impairment is associated with disease severity in multiple sclerosis. Mult Scler. 2014;20(9):1207–16. pmid:24399824.
- 20. Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, et al. Early retinal atrophy predicts long-term visual impairment after acute optic neuritis. Mult Scler. 2017;in press:1352458517718628. pmid:28669275.
- 21. Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, et al. The OSCAR-IB consensus criteria for retinal OCT quality assessment. PloS ONE. 2012;7(4):e34823. Epub 2012/04/27. PONE-D-11-21092 [pii]. pmid:22536333; PubMed Central PMCID: PMC3334941.
- 22. Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. Neurology. 2016;86(24):2303–9. pmid:27225223; PubMed Central PMCID: PMCPMC4909557.
- 23. Schinzel J, Zimmermann H, Paul F, Ruprecht K, Hahn K, Brandt AU, et al. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol. 2014;14:31. pmid:24555757; PubMed Central PMCID: PMC3932139.
- 24. Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A. Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler. 2012;18(7):991–9. Epub 2012/02/01. doi: 1352458511431972 [pii] pmid:22291035.
- 25. Balk LJ, Coric D, Nij Bijvank JA, Killestein J, Uitdehaag BM, Petzold A. Retinal atrophy in relation to visual functioning and vision-related quality of life in patients with multiple sclerosis. Mult Scler. 2017;in press:1352458517708463. pmid:28511578.
- 26. Longbrake EE, Lancia S, Tutlam N, Trinkaus K, Naismith RT. Quantitative visual tests after poorly recovered optic neuritis due to multiple sclerosis. Multiple sclerosis and related disorders. 2016;10:198–203. pmid:27919490; PubMed Central PMCID: PMCPMC5392253.
- 27. Jasse L, Vukusic S, Durand-Dubief F, Vartin C, Piras C, Bernard M, et al. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler. 2013;19(12):1618–26. pmid:23462348.
- 28. Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. "Seeing" in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler. 2013;19(7):953–60. pmid:23257618.
- 29. Owidzka M, Wilczynski M, Omulecki W. Evaluation of contrast sensitivity measurements after retrobulbar optic neuritis in Multiple Sclerosis. Graefes Arch Clin Exp Ophthalmol. 2014;252(4):673–7. pmid:24677004; PubMed Central PMCID: PMCPMC3968514.
- 30. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012;119(6):1250–7. pmid:22365058; PubMed Central PMCID: PMC3631566.